Concurrent Use of Ketotifen and Olopatadine

Rationale for Combination Therapy

Ketotifen is typically administered as an oral formulation or as ophthalmic drops, functioning as a sedating H1 receptor antagonist with systemic effects, according to the Journal of Allergy and Clinical Immunology 1
Olopatadine is available as topical ophthalmic solution or intranasal spray, providing targeted local delivery with minimal systemic absorption, as stated by the American Academy of Allergy, Asthma, and Immunology, and reported in the Journal of Allergy and Clinical Immunology, although the specific reference is from Praxis Medical Insights 2, 3

Guidelines recommend ketotifen as part of multi-agent antihistamine therapy for Mast Cell Activation Syndrome (MCAS), often combined with H1 and H2 blockers at different receptor sites, as recommended by the American Academy of Allergy, Asthma, and Immunology, and reported in the Journal of Allergy and Clinical Immunology 1
Patients may require both systemic antihistamine coverage (oral ketotifen) and targeted ocular therapy (olopatadine drops) for comprehensive symptom control in MCAS, according to the Journal of Allergy and Clinical Immunology 1
Systemic antihistamines like ketotifen may be used for atopic dermatitis or concomitant urticaria, though evidence for AD is limited, as reported in the Journal of Microbiology, Immunology and Infection 4
Olopatadine ophthalmic solution can be added specifically for allergic conjunctivitis symptoms that commonly accompany atopic conditions, as stated by the American Academy of Ophthalmology, and reported in Praxis Medical Insights 2, 3

Ketotifen is notably sedating, particularly during the first 2 weeks of treatment, and may cause cognitive impairment, as reported in the Journal of Allergy and Clinical Immunology 1
Olopatadine has minimal sedation risk with topical use, though intranasal formulation may cause somnolence in patients, as stated by the American Academy of Allergy, Asthma, and Immunology, and reported in Praxis Medical Insights 2
Monitor closely when initiating combination therapy, especially in elderly patients or those operating machinery, as recommended by the American Geriatrics Society, and reported in the Journal of Allergy and Clinical Immunology, and Praxis Medical Insights 1, 2
Ketotifen is contraindicated in patients with epilepsy, as convulsions have been reported with this agent, as reported in the Journal of Microbiology, Immunology and Infection 4

Systemic/multiple sites (rhinitis, urticaria, food allergy, MCAS) → Consider oral ketotifen, as recommended by the American Academy of Allergy, Asthma, and Immunology, and reported in the Journal of Allergy and Clinical Immunology 1
Isolated ocular symptoms → Start with olopatadine 0.1% ophthalmic solution, as stated by the American Academy of Ophthalmology, and reported in Praxis Medical Insights 3
Isolated nasal symptoms → Consider olopatadine 0.6% nasal spray, as recommended by the American Academy of Allergy, Asthma, and Immunology, and reported in Praxis Medical Insights 2